DCTA.L

Directa Plus Plc
Directa Plus PLC - Posting of Annual Report & Accounts
28th June 2024, 11:09
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3919U
Directa Plus PLC
28 June 2024
 

28 June 2024

 

Directa Plus plc

("Directa Plus", the "Group" or the "Company")

 

Posting of Annual Report & Accounts

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company's Annual Report and Accounts for the year ended 31 December 2023 and the Notice (the "Notice") of General Meeting ("GM") are being posted to shareholders today and are available on the Company's website at: https://www.directa-plus.com/financial-results/.

 

The GM will be held on Friday, 26 July 2024 at 3 p.m. at the offices of Vistra, 7th Floor, 50 Broadway, London SW1H 0DB.

 

For further information please visit or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO


Giorgio Bonfanti, CFO




Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald


Adam Rae




Singer Capital Markets Securities Limited (Joint Broker)

+44 20 7496 3069

Rick Thompson


Phil Davies




Alma Strategic Communications

+44 20 3405 0205

Justine James

directaplus@almastrategic.com

Hannah Campbell


Kinvara Verdon


 

 

Notes to Editors

 

Directa Plus (www.directa-plus.com) is one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets. The Company's graphene manufacturing capability uses proprietary patented technology based on a plasma super expansion process. Starting from natural graphite, each step of Directa Plus' production process - expansion, exfoliation and drying - creates graphene-based materials and hybrid graphene materials ready for a variety of uses and available in various forms such as powder, liquid and paste.

 

This proprietary production process uses a physical process, rather than a chemical process, to process graphite into pristine graphene nanoplatelets, which enables Directa Plus to offer a sustainable, non-toxic product, without unwanted by-products.

 

Directa Plus' products are made of hybrid graphene materials and graphene nano-platelets. The products (marketed as G+(R)) have multiple applications due to its properties. These G+(R) products can be categorised into various families, with different products being suitable for specific practical applications.

 

Directa Plus was established in 2005 and is based in Lomazzo (Como, Italy) and has been listed on the AIM market of the London Stock Exchange since May 2016. Directa Plus holds the Green Economy Mark from London Stock Exchange which recognises companies that contribute to the global green economy.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGUWRARSNUNUAR]]>
TwitterFacebookLinkedIn